Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

EvoXRare AI-Assisted Interpretation of Emergency Chest Radiographs (CXR-AI-RCT)

EvoXRare-Assisted Chest Radiograph Interpretation in Emergency and Critically Ill Adults: A Nationwide Multicenter Randomized Controlled Trial

Chest radiography is widely used in emergency departments, resuscitation rooms, intensive care units, and other acute-care settings. Clinically important abnormalities may be missed because findings are subtle, uncommon, obscured by overlapping anatomy, or encountered under high workload. This pragmatic randomized trial evaluates whether EvoXRare, an artificial intelligence system that provides a draft chest radiograph report and high-risk alerts for uncommon or clinically important abnormalities, reduces clinically important diagnostic misses compared with routine physician interpretation alone. Approximately 70,000 adults will be randomized 1:1 across 15-20 hospitals in China. The primary endpoint is the patient-level rate of clinically important abnormalities present on the reference standard but not reported in the initial clinical interpretation. Key secondary outcomes include detection of rare or easily missed findings, time to recognition of critical abnormalities, report turnaround time, false-positive alerts, additional imaging, recall/communication events, and selected short-term clinical outcomes.

Studieöversikt

Detaljerad beskrivning

This is a nationwide, multicenter, prospective, parallel-group, superiority randomized controlled trial with individual participant-level 1:1 allocation and blinded central endpoint adjudication. Eligible participants are adults undergoing clinically indicated chest radiography in emergency or critical-care settings. Only one index radiograph encounter per participant contributes to the primary randomized analysis.

In the control arm, physicians interpret the chest radiograph using the participating hospital's usual workflow without access to EvoXRare trial output. In the intervention arm, EvoXRare processes the same image on an independent AI workstation and provides a pre-generated report and/or high-risk prompts. The physician must review the original image, verify or edit the AI output, and remains responsible for the final report and all clinical communication. Both arms retain routine senior review and local critical-result procedures.

The AI model version, weights, preprocessing, thresholds, supported finding set, and report format are frozen before formal enrollment. No online learning or outcome-driven recalibration occurs during the randomized trial. If AI processing fails or images do not meet technical requirements, clinical care proceeds without delay and the participant remains in the assigned group for intention-to-treat analysis.

The reference standard is established by a blinded adjudication process using the index radiograph together with clinically available follow-up information, which may include subsequent CT, ultrasound, pathology, surgery, laboratory findings, clinical course, discharge diagnosis, or follow-up imaging. Adjudicators do not use the randomized assignment or EvoXRare output when determining whether a prespecified abnormality was present on the index radiograph.

The trial is designed primarily to test clinical diagnostic performance and workflow impact, not to retrain the AI system. It specifically emphasizes uncommon, high-consequence, and easily missed chest radiograph findings while also evaluating overall report quality and efficiency.

Studietyp

Interventionell

Inskrivning (Beräknad)

70000

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 90 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 18 years or older.
  • Undergoing a clinically indicated chest radiograph in a participating emergency department, resuscitation room, intensive care unit, or other prespecified acute/critical-care setting.
  • Chest radiograph is technically accessible to the study workflow before or during routine clinical interpretation.
  • The participant has not previously been randomized in this trial, unless the final protocol explicitly permits a separate recurrent-encounter analysis that does not enter the primary endpoint.
  • Consent or ethics-approved waiver/alteration of consent is satisfied according to the activated site protocol.

Exclusion Criteria:

  • Age younger than 18 years.
  • Image is missing, corrupted, or technically non-diagnostic to a degree that prevents clinical interpretation.
  • Radiograph was obtained solely for research rather than clinical care.
  • AI processing cannot be initiated because the image format or transfer route is outside the locked system specification; such cases may be recorded in screening logs but are not randomized unless the protocol allows post-randomization technical failure.
  • Prior randomization of the same participant in this trial for the primary participant-level analysis.
  • Any local legal, ethical, or institutional restriction that prevents study participation or required data use.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Diagnostisk
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: EvoXRare AI-Assisted Chest Radiograph Interpretation.

Usual chest radiograph interpretation plus access to EvoXRare-generated draft report and high-risk prompts. The physician reviews the original image, accepts/rejects/edits AI suggestions, submits the final report, and follows local critical-result communication procedures.

EvoXRare is an artificial intelligence software system that analyzes chest radiographs and provides draft reports and high-risk prompts to the interpreting physician. The physician reviews the original images and AI outputs and accepts, rejects, or edits the suggestions before finalizing the radiology report.

Inget ingripande: No Intervention / Active usual-care comparator: Standard Chest Radiograph Interpretation.

Routine physician interpretation according to the participating hospital's usual workflow, without access to EvoXRare trial output. Routine nontrial tools already in use may continue only if documented before site activation and applied consistently.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient-Level Clinically Important Abnormality Miss Rate on the Index Chest Radiograph
Tidsram: From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).

Proportion of randomized participants with at least one prespecified clinically important abnormality (Category A or B) judged present on the reference standard but absent from the initial finalized chest radiograph report produced under the assigned strategy.

From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 november 2027

Avslutad studie (Beräknad)

1 november 2028

Studieregistreringsdatum

Först inskickad

3 november 2026

Först inskickad som uppfyllde QC-kriterierna

3 november 2026

Första postat (Faktisk)

9 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • WHUH-CXR-AI-RCT-2026-11

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Yes, through controlled access subject to compatible consent/ethics approval and institutional authorization.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • ANALYTIC_CODE
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera